2020
Impaired Potentiation of Theta Oscillations During a Visual Cortical Plasticity Paradigm in Individuals With Schizophrenia
Hamilton HK, Roach BJ, Cavus I, Teyler TJ, Clapp WC, Ford JM, Tarakci E, Krystal JH, Mathalon DH. Impaired Potentiation of Theta Oscillations During a Visual Cortical Plasticity Paradigm in Individuals With Schizophrenia. Frontiers In Psychiatry 2020, 11: 590567. PMID: 33391054, PMCID: PMC7772351, DOI: 10.3389/fpsyt.2020.590567.Peer-Reviewed Original ResearchLong-term potentiationN-methyl-D-aspartate receptorsHealthy controlsNeuroplastic changesPlasticity paradigmsHigh-frequency electrical stimulationExperience-dependent synaptic plasticityVisual cortical plasticityPathophysiology of schizophreniaHigh-frequency stimulationNMDA receptor dysfunctionFrequency electrical stimulationTheta oscillationsVisual stimuliImpaired potentiationGlutamatergic transmissionReceptor dysfunctionImpaired neuroplasticityEvent-related EEG oscillationsNMDAR hypofunctionCortical plasticityVEP amplitudeAnimal modelsElectrical stimulationWhite checkerboard stimuli
2019
Enhancing the Utility of Preclinical Research in Neuropsychiatry Drug Development
Kaffman A, White JD, Wei L, Johnson FK, Krystal JH. Enhancing the Utility of Preclinical Research in Neuropsychiatry Drug Development. Methods In Molecular Biology 2019, 2011: 3-22. PMID: 31273690, PMCID: PMC6895673, DOI: 10.1007/978-1-4939-9554-7_1.Peer-Reviewed Original ResearchConceptsPreclinical researchAnimal modelsPsychiatric conditionsLower clinical success ratesClinical success rateCommon psychiatric conditionsPsychiatric clinical trialsClinical trialsNew pharmacotherapiesMore effective interventionsPreclinical workPsychiatric disordersPsychiatric pathophysiologyMental illnessSystematic reviewEffective interventionsAnimal experimentsDrug development processSuccess rateDrug developmentHuman psychopathologyPharmaceutical companiesPredictive validityLarge pharmaceutical companiesAnimals
2018
2. MICROCIRCUITS, MACROCIRCUITS, AND CORTICOL DYSFUNCTION IN SCHIZOPHRENIA: A COMPUTATIONAL AND TRANSLATIONAL NEUROSCIENCE PERSPECTIVE
Krystal J. 2. MICROCIRCUITS, MACROCIRCUITS, AND CORTICOL DYSFUNCTION IN SCHIZOPHRENIA: A COMPUTATIONAL AND TRANSLATIONAL NEUROSCIENCE PERSPECTIVE. Schizophrenia Bulletin 2018, 44: s1-s1. PMCID: PMC5887654, DOI: 10.1093/schbul/sby014.001.Peer-Reviewed Original ResearchNMDA glutamate receptorsNMDA receptor antagonistCortical functional connectivityPathophysiology of schizophreniaReceptor antagonistTranslational neuroscience perspectiveGlutamate receptorsHealthy humansAnimal modelsSchizophrenia patientsMemory impairmentNeuropsychiatric disordersSynaptic signalingFunctional connectivityNovel therapeuticsSchizophreniaDisordersPresentationPatientsPathophysiologyDysfunctionKetamineAntagonistSymptomsAbnormalities
2011
New Frontiers in Animal Research of Psychiatric Illness
Kaffman A, Krystal J. New Frontiers in Animal Research of Psychiatric Illness. Methods In Molecular Biology 2011, 829: 3-30. PMID: 22231804, PMCID: PMC3337084, DOI: 10.1007/978-1-61779-458-2_1.Peer-Reviewed Original ResearchConceptsPsychiatric illnessAnimal modelsMental illnessHuman psychopathologyValid animal modelCurrent animal modelsNumerous psychiatric disordersMore effective interventionsResearch Domain Criteria projectInternational ClassificationPsychiatric disordersMeasurable endophenotypesIllnessNeurodevelopmental changesSubstance abuseEffective interventionsAnxiety disordersStatistical ManualMolecular changesDevelopmental originsMental disorders diagnostic systemsCircuit developmentTranslational workAnimal researchBehavioral outcomes
2010
Potential Psychiatric Applications of Metabotropic Glutamate Receptor Agonists and Antagonists
Krystal JH, Mathew SJ, D’Souza D, Garakani A, Gunduz-Bruce H, Charney DS. Potential Psychiatric Applications of Metabotropic Glutamate Receptor Agonists and Antagonists. CNS Drugs 2010, 24: 669-693. PMID: 20658799, DOI: 10.2165/11533230-000000000-00000.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsPreliminary clinical trialsPositive allosteric modulatorsPsychiatric disordersClinical trialsAnimal modelsAllosteric modulatorsGroup II mGluR agonistGroup IMetabotropic glutamate receptor agonistAnxiety disordersPotential psychiatric applicationsGlutamate receptor agonistsMetabotropic glutamate receptorsTreatment of schizophreniaRole of glutamateForm of depressionMGluR agonistAntidepressant propertiesMGluR5 agonistReceptor agonistGlutamate receptorsMood disordersArea of schizophreniaPromising agentAgonistsSerotonin 1B Receptor Imaging in Alcohol Dependence
Hu J, Henry S, Gallezot JD, Ropchan J, Neumaier JF, Potenza MN, Sinha R, Krystal JH, Huang Y, Ding YS, Carson RE, Neumeister A. Serotonin 1B Receptor Imaging in Alcohol Dependence. Biological Psychiatry 2010, 67: 800-803. PMID: 20172504, PMCID: PMC3112181, DOI: 10.1016/j.biopsych.2009.12.028.Peer-Reviewed Original ResearchConceptsHealthy control subjectsAlcohol dependencePositron emission tomographyStriatal 5Emission tomographyMagnetic resonance imaging (MRI) scansIndividual magnetic resonance imaging (MRI) scansMultilinear reference tissue modelResonance imaging scansSerotonin 1B receptorReference tissue modelClinical variablesAbstinent patientsControl subjectsImaging scansAnatomical abnormalitiesHC subjectsRodent modelsAntagonist radioligandReceptor imagingAnimal modelsVivo assessmentTomographyFirst evidenceHigh-resolution research tomograph
2007
Imaging the Neurochemistry of Alcohol and Substance Abuse
Martinez D, Kim JH, Krystal J, Abi-Dargham A. Imaging the Neurochemistry of Alcohol and Substance Abuse. Neuroimaging Clinics Of North America 2007, 17: 539-555. PMID: 17983969, DOI: 10.1016/j.nic.2007.07.004.Peer-Reviewed Original ResearchThe NMDA receptor as a therapeutic target in major depressive disorder.
Pittenger C, Sanacora G, Krystal JH. The NMDA receptor as a therapeutic target in major depressive disorder. CNS & Neurological Disorders - Drug Targets 2007, 6: 101-15. PMID: 17430148, DOI: 10.2174/187152707780363267.Peer-Reviewed Original ResearchConceptsMajor depressive disorderNMDA receptorsDepressive disorderNovel antidepressant medicationsCognitive side effectsPotential of drugsAntidepressant medicationAntidepressant propertiesSuch medicationsGlutamatergic neurotransmissionGlutamate receptorsPreclinical studiesPsychotomimetic propertiesSide effectsTherapeutic targetAnimal modelsUseful agentNeurotransmissionReceptorsLines of evidenceMedicationsDisordersDrugsCurrent knowledgeDepression
1993
Yohimbine — facilitated acoustic startle reflex in humans
Morgan CA, Southwick SM, Grillon C, Davis M, Krystal JH, Charney DS. Yohimbine — facilitated acoustic startle reflex in humans. Psychopharmacology 1993, 110: 342-346. PMID: 7831429, DOI: 10.1007/bf02251291.Peer-Reviewed Original ResearchConceptsAcoustic startle reflexHealthy subjectsRandomized double-blind placebo-controlled designStartle amplitudeDouble-blind placebo-controlled designStartle reflexAlpha-2 receptor antagonistEffects of yohimbinePlacebo-controlled designDB intensityUseful animal modelHealthy human subjectsInstantaneous rise timeSaline placeboCardiovascular effectsExcitatory effectsNoradrenergic functionReceptor antagonistPlasma MHPGPreclinical studiesPeak anxietyYohimbineNeurochemical basisAnimal modelsRank testing